Phatak P D, Sham R L, Raubertas R F, Dunnigan K, O'Leary M T, Braggins C, Cappuccio J D
Mary M. Gooley Hemophilia Center, Inc., Rochester General Hospital, and the University of Rochester School of Medicine and Dentistry, New York 14621, USA.
Ann Intern Med. 1998 Dec 1;129(11):954-61. doi: 10.7326/0003-4819-129-11_part_2-199812011-00006.
Despite evidence from screening studies in northern European populations, the prevalence of hemochromatosis in primary care populations in the United States remains speculative.
To establish the feasibility of screening for hemochromatosis and to estimate the prevalence of hemochromatosis in a large primary care population.
Cross-sectional prevalence study.
22 primary care practices in the Rochester, New York, area.
16031 ambulatory patients without a previous diagnosis of hemochromatosis.
Serum transferrin saturation screening tests were offered to all adult patients in participating primary care practices.
Patients with a serum transferrin saturation of 45% or more on initial testing had a serum transferrin saturation test done under fasting conditions and had serum ferritin levels measured. Those who had a fasting serum transferrin saturation of 55% or more and a serum ferritin level of 200 microg/L or more with no other apparent cause were presumed to have hemochromatosis and were offered liver biopsy to confirm the diagnosis.
25 patients had biopsy-proven hemochromatosis; 22 patients met the clinical criteria for hemochromatosis but declined liver biopsy and were classified as having clinically proven hemochromatosis; and 23 patients had a serum transferrin saturation of 55% or more with no identifiable cause, indicating probable hemochromatosis. The prevalence of clinically proven and biopsy-proven hemochromatosis combined was 4.5 per 1000 (95% CI, 3.3 to 5.8 per 1000) in the total sample and 5.4 per 1000 (CI, 4.0 to 7.1 per 1000) in white persons. The prevalence was higher in men than in women (ratio, 1.8:1).
Hemochromatosis is relatively common among white persons. Routine screening of white persons for hemochromatosis should be considered by primary care physicians.
尽管北欧人群的筛查研究有相关证据,但美国初级保健人群中铁代谢紊乱的患病率仍属推测。
确定铁代谢紊乱筛查的可行性,并估计大型初级保健人群中铁代谢紊乱的患病率。
横断面患病率研究。
纽约罗切斯特地区的22家初级保健机构。
16031名此前未被诊断为铁代谢紊乱的门诊患者。
为参与研究的初级保健机构中的所有成年患者提供血清转铁蛋白饱和度筛查测试。
初次检测血清转铁蛋白饱和度达到或超过45%的患者,在空腹条件下进行血清转铁蛋白饱和度测试,并测量血清铁蛋白水平。空腹血清转铁蛋白饱和度达到或超过55%且血清铁蛋白水平达到或超过200μg/L且无其他明显病因的患者,被推定为患有铁代谢紊乱,并接受肝活检以确诊。
25例患者经活检证实患有铁代谢紊乱;22例患者符合铁代谢紊乱的临床标准,但拒绝肝活检,被归类为临床确诊的铁代谢紊乱;23例患者血清转铁蛋白饱和度达到或超过55%且无明确病因,表明可能患有铁代谢紊乱。在整个样本中,临床确诊和活检证实的铁代谢紊乱合并患病率为每1000人中有4.5例(95%可信区间,每1000人中有3.3至5.8例),在白人中为每1000人中有5.4例(可信区间,每1000人中有4.0至7.1例)。男性患病率高于女性(比例为1.8:1)。
铁代谢紊乱在白人中相对常见。初级保健医生应考虑对白人进行铁代谢紊乱的常规筛查。